ACTINIUM PHARMACEUTICALS news, videos and press releases
For more news please use our advanced search feature.
ACTINIUM PHARMACEUTICALS - More news...
ACTINIUM PHARMACEUTICALS - More news...
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
- Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
- Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
- Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
- Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
- Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
- Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
- Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
- Actinium Appoints Lynn Bodarky as Chief Business Officer
- Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
- Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
- Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
- Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
- Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO
- Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting
- Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress
- Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
- SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data
- Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting
- Actinium Pharma to Present at the Maxim Healthcare Virtual Conference
- Actinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit
- Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress
- Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes
- Actinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Solid Cancers
- Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)
- Actinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day
- Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the Pivotal Phase 3 SIERRA Trial at the 48th Annual Oncology Nursing Society (ONS) Congress